News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Reach Announces Collaboration With Evotec AG (EVTG.F)

3/19/2014 9:42:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

March 2014 -- REACH Separations has struck a strategic alliance with Evotec, which will see the UK-based company provide additional purification and analytical capability to support Evotec’s pharmaceutical and biotech clients worldwide.

As part of the deal, the purification specialist will become a technology partner to Evotec and be responsible for providing expertise in small molecule chromatography.

The two companies have developed a working partnership since 2012, which has provided a solid foundation for this official agreement.

The move was initiated by Evotec in a bid to support its expanded chemistry group by further improving the turnaround of chiral analysis and purification on client projects, without needing to make significant investment in additional equipment and facilities.

Located in BioCity in Nottingham, Reach Separations is capable of purifying from mg scale to in excess of 250g. It will now look after all chiral purification above 0.3g and 50% of all chiral analysis and purification under 0.3g for Evotec.

Reach Separations’ technical group is led by technical director Phil Abbott, who has worked in the pharmaceutical industry for almost 20 years, including several years at AstraZeneca as a Separation Science Group Leader.

Peter Ridgway, business development director at Reach Separations, said: “We are delighted to have struck a collaboration with one of the world’s leading drug discovery research organisations. Given the existing scientific knowledge available within the team at Evotec, this deal demonstrates the high level of purification and analytical expertise we are able to bring to such projects.

“To support the increasing workload this new partnership brings, we have invested in expanded laboratory space, taken on more scientists and increased our instrumentation capability ensuring we are consistently able to deliver not only for Evotec and its clients but for our developing client base as a whole.”

Evotec is a drug discovery and development expert focused on rapidly progressing product approaches with pharmaceutical and biotechnology companies worldwide. Headquartered in Hamburg, the company has major operations in Abingdon, UK, Göttingen, Munich, Germany, San Francisco and Branford, USA.

Dr David Hallett, executive vice president of discovery chemistry at Evotec, said: “The team at Reach Separations has considerable expertise in the fields of chiral, reverse phase and normal phase chromatography that will help our in-house team with added expertise and resource.

“By adding Reach Separations to our exclusive portfolio of technology partners, it will allow us to streamline our processes that will allow us to meet clients’ project milestones even quicker.”

The partnership is well under way with Reach Separations collecting and delivering samples at least twice weekly to support the Evotec chemistry group.

This is the latest strategic alliance for the team at Reach Separations, which has a strong track record in the pharmaceutical outsourcing sector. The company already works closely with chemistry expert Onyx Scientific, providing custom separation for companies in drug discovery and intermediate environments. |

Picture caption: DEAL: Evotec's Dr David Hallett with Reach Separations’ Peter Ridgway at Evotec’s UK labs

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus
Evotec AG